Compare · GLP-1 agonist
Retatrutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | Semaglutide | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.